Filtered By:
Condition: Heart Failure
Nutrition: Sodium

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 255 results found since Jan 2013.

SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Abstract Sodium-glucose co-transporter-2 (SGLT2) inhibitor drugs are effective for treatment of type-2 diabetes mellitus. These medications target the SGLT2 transporter in the proximal convoluted tubule to prevent reabsorption of filtered glucose, resulting in glucosuria. Other clinically meaningful benefits beyond glycemic control include reductions in blood pressure, weight, and albuminuria. Three large clinical trials and subsequent meta-analyses studying SGLT2 inhibitors demonstrated significant cardiovascular benefits including reductions in heart failure hospitalizations, as well as reduced risk of myocardia...
Source: Journal of Nephrology - February 17, 2020 Category: Urology & Nephrology Authors: Baker ML, Perazella MA Tags: J Nephrol Source Type: research

Sodium Handling and Interaction in Numerous Organs.
Abstract Salt (NaCl) is a prerequisite for life. Excessive intake of salt, however, is said to increase disease risk including hypertension, arteriosclerosis, heart failure, renal disease, stroke, and cancer. Therefore, considerable research has been expended on the mechanism of sodium handling based on the current concepts of sodium balance. The studies have necessarily relied on relatively short-term experiments and focused on extremes of salt intake in humans. Ultra-long-term salt balance has received far less attention. We performed long-term salt balance studies at intakes of 6, 9, and 12 g/day and found that...
Source: American Journal of Hypertension - March 20, 2020 Category: Cardiology Authors: Minegishi S, Luft FC, Titze J, Kitada K Tags: Am J Hypertens Source Type: research

Correlation among high salt intake, blood pressure variability, and target organ damage in patients with essential hypertension: Study protocol clinical trial (SPIRIT compliant)
This study is a cross-sectional study. It will recruit 600 patients with essential hypertension in the outpatient and inpatient department of cardiovascular medicine of Chengdu Fifth People's Hospital. Researchers will obtain blood and urine samples with the patient's informed consent. In addition, we will measure patient's blood pressure and target organ-related information. Trial registry: The study protocol was approved by the Chengdu Fifth People's Hospital. Written informed consent will be obtained from all the participants. The trial was registered in the Chinese Clinical trial registry, ChiCTR2000029243. This tri...
Source: Medicine - April 1, 2020 Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
CONCLUSION: In diabetic patients at low cardiovascular risk, no treatment differs from placebo for vascular outcomes. In patients at increased cardiovascular risk receiving metformin-based background therapy, specific GLP-1 RAs and SGLT-2 inhibitors have a favorable effect on certain cardiovascular outcomes. PRIMARY FUNDING SOURCE: European Foundation for the Study of Diabetes, supported by an unrestricted educational grant from AstraZeneca. (PROSPERO: CRD42019122043). PMID: 32598218 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - June 29, 2020 Category: Internal Medicine Authors: Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, Liakos A, Matthews DR, Bekiari E Tags: Ann Intern Med Source Type: research

A Call for a New Paradigm for Diabetes Care in the Era of Sodium –Glucose Cotransporter 2 Inhibitors (SGLT2i)
This article is based on previously conducted studies and the authors disclose  their roles in relevant trials in the Acknowledgements.
Source: Cardiology and Therapy - July 12, 2020 Category: Cardiology Source Type: research

Sodium –glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
In conclusion, SGLT2i initiators had lower risks of cardiovascular events versus other glucose‐lowering drug initiators and, uniquely, versus DPP4i initiators in Japanese real‐world practice.
Source: Journal of Diabetes Investigation - July 25, 2020 Category: Endocrinology Authors: Shun Kohsaka, Masayoshi Takeda, Johan Bodeg ård, Marcus Thuresson, Mikhail Kosiborod, Toshitaka Yajima, Eric Wittbrodt, Peter Fenici Tags: Short Report Source Type: research

Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors in Thai adults with type 2 diabetes mellitus: a real-world study.
Conclusions: SGLT2i improved cardiometabolic parameters in Thai adults, clinically, confirming findings in controlled trials. PMID: 32776785 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - August 13, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Meta-analysis Assessing the Effect of Sodium-glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients with Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) has evolved as a pandemic of the 21st century, while cardiovascular disease (CVD) affects almost one third of patients and represents the cause of death in more than half cases, with coronary artery disease, heart failure (HF) and stroke being the main contributors.1 Hallmark cardiovascular outcome trials published during the last five years have established a novel class of antidiabetics, namely sodium-glucose co-transporter-2 (SGLT-2) inhibitors as a primary treatment option in patients with HF, atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease (CKD), along with the ...
Source: The American Journal of Cardiology - August 6, 2020 Category: Cardiology Authors: Dimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, Maria-Styliani Kalogirou, Michael Doumas Source Type: research

Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients 　- A Randomized Controlled Trial.
CONCLUSIONS: Dapagliflozin significantly improved RVSP and LVFP during exercise in patients with T2DM and cardiovascular risk, which may contribute to favorable effects on heart failure. PMID: 32921680 [PubMed - as supplied by publisher]
Source: Circulation Journal - September 11, 2020 Category: Cardiology Authors: Kayano H, Koba S, Hirano T, Matsui T, Fukuoka H, Tsuijita H, Tsukamoto S, Hayashi T, Toshida T, Watanabe N, Hamazaki Y, Geshi E, Murakami M, Aihara K, Kaneko K, Yamada H, Kobayashi Y, Shinke T Tags: Circ J Source Type: research

In reply —Risk Framing in Cardiovascular Medicine I and II
We thank the authors for their insightful comments on our perspective published in the journal.1 We agree with Dr Modarressi1 that sodium-glucose cotransporter-2 inhibitors indeed represent an important new treatment for patients with heart failure. Although we used the trial definition of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or stroke) in the text and in the table ’s footnote, we acknowledge that this was a secondary and not a primary end point.
Source: Mayo Clinic Proceedings - November 1, 2020 Category: Internal Medicine Authors: Mohamad Alkhouli, Charanjit S. Rihal Tags: Letter to the editor Source Type: research

Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis.
CONCLUSIONS: Both GLP-1 agonists and SGLT-2 inhibitors showed comparable cardiovascular outcomes in patients with type 2 diabetes. However, the SGLT-2 inhibitors were associated with more pronounced reduction of hospitalization for HF and lower risk of treatment discontinuation than GLP-1 agonists. PMID: 33140391 [PubMed - as supplied by publisher]
Source: Cardiology Journal - November 3, 2020 Category: Cardiology Authors: Lee YM, Lee SH, Kim TH, Park EJ, Park YA, Jang JS Tags: Cardiol J Source Type: research

SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients.
Conclusion: SGLT2 inhibitors are novel antidiabetic medications with immense utility in the management of patients with T2DM. Furthermore, SGLT2 inhibitors have demonstrated to reduce the progression to advanced forms of kidney disease and its associated complications. These medications should be front and center in the management of patients with diabetic kidney disease with and without chronic kidney disease as they confer protection against cardiovascular/renal death and improve all-cause mortality. Future studies should evaluate the benefits and implications of early initiation of SGLT2 inhibitors, as well as the long-...
Source: International Journal of Nephrology and Renovascular Disease - November 7, 2020 Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research

Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
ConclusionCompared with placebo, SGLT-2i may reduce the risk of heart failure hospitalization, MACE, and cardiovascular death. Therefore, SGLT-2i may be an ideal choice for type 2 diabetes mellitus patient with heart failure. These results will help inform practitioners, patients, and authorities making appropriate choices in hypoglycemic therapy clinical practice.
Source: Frontiers in Endocrinology - January 15, 2021 Category: Endocrinology Source Type: research

Efficacy of Beraprost Sodium Combined with Sildenafil and Its Effects on Vascular Endothelial Function and Inflammation in Patients Experiencing Left Heart Failure Complicated with Pulmonary Arterial Hypertension.
CONCLUSIONS Beraprost sodium combined with sildenafil for left heart failure complicated with pulmonary arterial hypertension can effectively improve pulmonary arterial hypertension, alleviate left heart failure, and reduce inflammatory responses, thereby achieving better clinical efficacy in patients. PMID: 33531453 [PubMed - in process]
Source: Medical Science Monitor - February 5, 2021 Category: Research Tags: Med Sci Monit Source Type: research

Efficacy and safety of Shenfu injection combined with sodium nitroprusside in the treatment of chronic heart failure in patients with coronary heart disease: A protocol of randomized controlled trial
This study will evaluate the efficacy and safety of Shenfu injection combined with sodium nitroprusside in the treatment of chronic heart failure in patients with coronary heart disease. The results of this experiment will provide a clinical basis for Shenfu injection combined with sodium nitroprusside in the treatment of chronic heart failure in coronary heart disease. Trial registration: DOI 10.17605/OSF.IO/4KNG3
Source: Medicine - February 19, 2021 Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research